BridgeBio Pharma, Inc. (BBIO) Stock AnalysisBBIOBridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

BridgeBio Pharma Inc is a good buy right now due to its current price of $66.39, which is significantly lower than the analyst price targets ranging from $94 to $157. The company has shown a gross margin of 93.83% in Q2 2026, indicating strong profitability potential. Additionally, the recent partnership with the U.S. government to enhance drug access could drive future revenue growth. However, the main risk is the negative net income, which was -$155,891,000 in Q2 2026, indicating ongoing financial challenges that investors should monitor closely.